Overall, authors of systematic reviews and meta-analyses have concluded there is little conclusive evidence to support the use of these biomarkers in diagnosis or risk assessment for osteoporosis [34, 35, 37, 45, 57], a conclusion consistent with our findings with the possible exception of sclerostin in men. Here, SOST is linked to osteoporosis.